H.C. Wainwright Thinks Anavex Life Sciences’ Stock is Going to Recover

H.C. Wainwright analyst Ram Selvaraju reiterated a Buy rating on Anavex Life Sciences (AVXLResearch Report) today and set a price target of $42.00. The company’s shares closed last Tuesday at $10.65, close to its 52-week low of $9.28.

According to, Selvaraju has currently 0 stars on a ranking scale of 0-5 stars, with an average return of -33.9% and a 17.3% success rate. Selvaraju covers the Healthcare sector, focusing on stocks such as Reviva Pharmaceuticals Holdings, Aquestive Therapeutics, and Vallon Pharmaceuticals.

Anavex Life Sciences has an analyst consensus of Strong Buy, with a price target consensus of $30.40.

See Insiders’ Hot Stocks on TipRanks >>

Based on Anavex Life Sciences’ latest earnings release for the quarter ending December 31, the company reported a quarterly GAAP net loss of $10.88 million. In comparison, last year the company had a GAAP net loss of $7.86 million.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Anavex Life Sciences Corp. is a clinical stage biopharmaceutical company, which engages in the development of different therapeutics for the treatment of neurodegenerative and neurodevelopmental diseases. Its lead compound, ANAVEX2-73, is being developed to treat Alzheimer’s and Parkinson’s disease and central nervous system diseases, including Rett syndrome. The company was founded by Harvey Lalach and Athanasios Skarpelos on January 23, 2004 and is headquartered in New York, NY.

Read More on AVXL:

Tired of arriving late to the Big Returns Party?​
Most investors don’t have major gainers like TSLA or NVDA on their radar from the start.
The profusion of opinions on social media and financial blogs makes it impossible to distinguish between real growth potential and pure hype.
​​For the past decade, we have developed and perfected technology designed to help private investors, just like you, find the best opportunities, with the greatest upside potential, in any financial climate.​
Learn More